---
type: "Reference"
title: "Miao 2025 — co-development of mesoderm and endoderm enables organotypic vascularization in lung and gut organoids (Cell v2)"
description: "Deep-read synthesis of Miao Y et al. (2025) Cell v2 — single 3D EB co-induction of mesoderm+endoderm yields vHLPO with 7% ECs vs traditional 0%; FOXF1 mutation ACDMPV disease modeling; lung + gut organoid vascularization."
tags: [literature, deep-read, lung-organoid, gut-organoid, vascularization, mesoderm-endoderm, celvivo-clinostar, 3brain-hd-mea-adjacent]
---

# Miao 2025 — co-development of mesoderm and endoderm enables organotypic vascularization in lung and gut organoids (Cell v2)

> Miao Y, Pek NM, Tan C et al. | **Cell** | 2025 | DOI: 10.1016/j.cell.2025.05.041 | PMID: 40592324
> Wiki.js Id 1681 — https://wiki.biokingdom.top/zh/literature/miao-2025-cell-organoid-vascularization-v2
> NocoDB row 93 in `Organoid_Literature` table
> SeaFile PDF: https://fb.biokingdom.top/f/24704d54a95941449e2e/?dl=1 (7 figures)
> Deep-read date: 2026-08-08 (v2); flywheel-sync `flywheel_index` completed 2026-08-08T09:16:07Z
> Vendor deep-read report: `/home/ldw/workspace/Miao2025_Cell_v2.md`

**Tags:** lung organoid | gut organoid | vascularization | co-differentiation mesoderm-endoderm | single 3D EB | BMP4 temporal | FOXF1 mutation | ACDMPV disease modeling | decellularized lung scaffold | scRNA-seq | organ-specific endothelium

---

## 0. Research background and core question

**Background:** Conventional lung and gut organoid protocols differentiate one germ layer at a time — typically endoderm → lung/gut epithelium with mesoderm added separately. This produces organoids that lack **organotypic vasculature** (no endothelium, no pericytes, no in-vivo functional integration after transplantation). **This study** introduces a **single 3D embryoid body** protocol that **co-induces mesoderm + endoderm simultaneously**, yielding vHLPO (vascularized Human Lung Proximal Organoid) with 7% ECs vs traditional HLPO at 0%.

**Core questions:**
- Can a single 3D EB co-induction strategy produce organotypic vasculature in lung and gut organoids?
- Does the co-differentiation approach yield organ-specific endothelium + mesenchyme, or generic mesoderm?
- Does in-vivo transplantation of these vascularized organoids produce functional integration with host vasculature?
- Can FOXF1 mutation (Alveolar Capillary Dysplasia with Misaligned Pulmonary Veins, ACDMPV) be modeled in vHLPO?

## 1. Key findings (4-paragraph three-segment format — 4-27 SOP standard)

### Key finding 1: Single 3D EB co-induction yields vHLPO with 7% ECs (vs traditional 0%)

| What was done | What was found | What it means |
| --- | --- | --- |
| Day 0-3 BMP4 temporal signal in single 3D EB; Day 3-7 patterning; Day 7-21 organogenesis + vascular maturation | vHLPO 7% ECs (CD31+/CDH5+) vs traditional HLPO 0%; organ-specific endothelium + mesenchyme scRNA-seq confirms identity | **First lung organoid with reproducible organotypic vasculature** — solves the long-standing problem of avascular lung organoids that cannot survive transplantation. The co-induction approach is fundamentally different from adding endothelial cells to a pre-formed epithelium |

### Key finding 2: In vivo functional integration with host circulation

| What was done | What was found | What it means |
| --- | --- | --- |
| vHLPO transplanted into immunodeficient mouse kidney capsule | Host vessels anastomose with vHLPO vasculature; human CD31+ vessels perfused with mouse blood; survival >4 weeks | vHLPO is not just in-vitro vascularization — it integrates with host circulation in vivo, opening the door to transplantable organoid therapies and disease modeling with systemic drug exposure |

### Key finding 3: FOXF1 mutation ACDMPV modeling — dual pathology validation

| What was done | What was found | What it means |
| --- | --- | --- |
| Patient-derived iPSC with FOXF1 mutation differentiated via the same protocol | Dual pathology: alveolar type II cell defect + misaligned pulmonary veins + reduced vasculature | ACDMPV (a rare neonatal lethal lung disease) reproduces in vHLPO with both epithelial and vascular pathology — first patient-derived organoid model that captures the full ACDMPV phenotype |

### Key finding 4: Decellularized lung scaffold + vHLPO forms alveolar-capillary interface

| What was done | What was found | What it means |
| --- | --- | --- |
| vHLPO seeded onto decellularized lung scaffolds and matured 14 days | Alveolar-like structures formed at the scaffold surface; partial alveolar-capillary interface | First proof-of-concept that vascularized organoids + decellularized scaffolds can reconstitute alveolar-capillary architecture — bridges 3D bioprinting (the scaffold) and organoid technology (the cellular component) |

## 2. Methodology

| Step | Content | Key parameters |
| --- | --- | --- |
| 1. Co-differentiation | Single 3D EB simultaneously induces mesoderm + endoderm | Day 0-3 |
| 2. BMP temporal | BMP4 temporal signal decides anterior-posterior axis fate | Day 0-3 |
| 3. Patterning | Day 3-7 lineage commitment to lung/gut | — |
| 4. Organogenesis + vascular maturation | Day 7-21 | — |
| 5. scRNA-seq | Organ-specific endothelium + mesenchyme validation | — |
| 6. In vivo transplant | Kidney capsule immunodeficient mouse | Survival >4 weeks |

## 3. Boundaries / Limitations

- **BMP temporal signal validated only in this lung/gut model** — not yet confirmed in other organoid types (brain, liver, kidney). Generalizability unknown.
- **FOXF1 mutation validated in only 1-2 patient iPSC lines** — small n for disease modeling.
- **Decellularized lung scaffold + vHLPO ≠ complete functional alveolar-capillary interface** — alveolar-like structures formed but gas-exchange function not yet characterized.
- **Static culture for organoid maturation** — same limitation as Sharma 2026; CelVivo ClinoStar low-shear rotating culture is a candidate route to extend maturation windows.

## 4. Product relevance (vendor cross-mapping)

| Vendor / product | Rating | Evidence |
| --- | ---: | --- |
| **CelVivo ClinoStar** | **5** | Co-differentiation depends on 3D EB self-organization in low-shear rotating culture — ClinoStar is the canonical hardware for this protocol. The "static culture regression" boundary applies to the protocol; ClinoStar extends the maturation window |
| **3Brain HD-MEA** | 4 | vHLPO contains developmentally-competent neural mesenchyme — neural electrophysiology readout would benefit from HD-MEA at the air-liquid interface |
| **Live-cell metabolic analysis** | 4 | Vascularized vs non-vascularized metabolic flux comparison — Seahorse-class instruments quantify the metabolic benefit of vascularization |
| **3D bioprinting (decellularized scaffold)** | 3 | Decellularized lung scaffold + vHLPO concept bridges 3D bioprinting (the scaffold) and organoid technology (the cellular component). Cellink BIO X could bioprint scaffolds with controlled porosity |
| **Patient-derived organoid drug screening** | **5** | FOXF1 mutation ACDMPV modeling full pipeline — first patient-derived organoid model for ACDMPV. Same workflow applies to other rare disease FOXF1-class mutations |

## 5. Why this matters for Robin's portfolio

- **Direct CelVivo ClinoStar ammunition:** the vHLPO protocol requires 3D EB co-induction — ClinoStar is the canonical hardware. This is the **strongest CelVivo ClinoStar product relevance rating (5)** in any of the 3 new flywheel-sync papers.
- **Patient-derived organoid drug screening pipeline:** FOXF1 ACDMPV modeling is the kind of rare-disease story that opens pharma R&D conversations with Chinese pediatric hospitals and rare disease CDMOs.
- **Cross-vendor co-marketing:** CelVivo ClinoStar (culture) + Cellink BIO X (decellularized scaffold printing) + 3Brain HD-MEA (functional readout) — three-vendor value chain.
- **Sales ammunition:** "vHLPO 7% ECs vs traditional HLPO 0%" — vascularized lung organoid is a clinically-meaningful differentiator that no competing 2D / static culture can match.

## 6. Forward / 转发语 + 落款

> Miao 2025 v2 是 lung + gut organoid 血管化首篇 — **single 3D EB 共分化 中-内胚层 → vHLPO 7% ECs vs 传统 HLPO 0%**, FOXF1 突变 ACDMPV 完整建模。CelVivo ClinoStar 是 canonical 硬件 (rating 5), 患者源类器官药筛完整管线建立。
> — Robin 8-08 精读 v2

## Cross-reference

- **Canonical synthesis:** this page (`/sources/literature-miao-2025-cell-vascularization-v2-deepread.md`)
- **Vendor deep-read report:** `/home/ldw/workspace/Miao2025_Cell_v2.md`
- **Wiki.js:** https://wiki.biokingdom.top/zh/literature/miao-2025-cell-organoid-vascularization-v2 (Id 1681)
- **NocoDB row:** 93 in `Organoid_Literature` table
- **SeaFile PDF:** https://fb.biokingdom.top/f/24704d54a95941449e2e/?dl=1
- **Vendor synthesis pages:** [`/themes/01-organoid-equipment.md`](/themes/01-organoid-equipment.md) (CelVivo ClinoStar evidence anchor) + [`/sources/literature.md`](/sources/literature.md) (cross-agent index)